To evaluate the efficacy of golimumab on severe and frequent recurrent anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis. In this study, 15 eyes of 12 HLA-B27-positive AS patients with resistant anterior uveitis who received 50 mg of subcutaneous golimumab (Gol) per month due to frequent uveitis recurrences were analyzed retrospectively between May 2013 and October 2015. Assessment criteria were uveitis activity, the number of recurrence of uveitis, visual acuity, systemic corticosteroid, or other drug requirement for maintenance of remission of AU. Twelve patients (15 eyes) with HLA-B27-positive ankylosing spondylitis and anterior uveitis have been treated with golimumab 50 mg/month. Remission of uveitis was observed in 12 eyes out of 15. Malign hypertension developed in one subject after the second dose of golimumab therefore the treatment was stopped and this subject was excluded from the study. Median follow-up time was 11 months (interquartile range: 8–18). No uveitic reaction was seen except in the patient who stopped treatment. No topical or systemic steroid necessity was needed except in two cases with oral 4 mg systemic maintenance. Visual acuity was significantly increased (p = 0.002). Golimumab may be a new and effective choice for maintaining remission and the prevention of recurrences of severe, resistant anterior uveitis in patients with HLA-B27-positive ankylosing spondylitis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Stolwijk C, van Tubergen A, Castillo-Ortiz JD et al (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74:65–73
Khan MA (1992) An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin North Am 18(1):1–10 (Review)
Rosenbaum JT (1992) Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am. 18(1):143–151 (Review)
Robinson PC, Brown MA (2014) Genetics of ankylosing spondylitis. Mol Immunol 57(1):2–11
Yao Q (2013) Nucleotide-binding oligomerization domain containing 2: structure, function, and diseases. Semin Arthritis Rheum 43(1):125–130
Martin TM, Smith JR, Rosenbaum JT (2002) Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 14(4):337–341 (Review)
Max R, Lorenz HM, Mackensen F (2010) Ocular involvement in spondyloarthropathies: HLA B27 associated uveitis. Z Rheumatol 69(5):397–402 (Review)
Careless DJ, Inman RD (1995) Acute anterior uveitis: clinical and experimental aspects. Semin Arthritis Rheum. 24(6):432–441 (Review)
Loh AR, Acharya NR (2010) Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol 150(4):534–542. doi:10.1016/j.ajo.2010.04.031
Labalette P (2011) Refractory anterior uveitis. J Fr Ophtalmol 34(2):122–126
Byun YS, Park YH (2009) Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther 25(2):159–162
Fitzgerald JT, Saunders L, Ridge B, White AJ, Goldberg I, Clark B, Mills RA, Craig JE (2015) Severe intraocular pressure response to periocular or intravitreal steroid treatment in Australia and New Zealand: data from the Australian and New Zealand Ophthalmic Surveillance Unit. Clin Exp Ophthalmol 43(3):234–238
Foster CS, Kothari S, Anesi SD, Vitale AT, Chu D, Metzinger JL, Cerón O (2015) The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol 61:1–17
Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T et al (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 14(Pt 3A):340–343
Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42(11):2325–2329
Levy-Clarke G, Nussenblatt R (2006) Does anti-TNF therapy decrease the incidence of anterior uveitis in patients with ankylosing spondylitis? Nat Clin Pract Rheumatol 2(2):72–73
Guignard S, Gossec L, Salliot C et al (2006) Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondyloarthropathy: a retrospective study. Ann Rheum Dis 65(12):1631–1634
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516 (Review)
Rudwaleit M, Rødevand E, Holck P et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701
Rosenbaum JT (2004) Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 50(11):3736–3737
Bodaghi B, Wechsler B, Du-Boutin LT et al (2003) Chronic severe uveitis: classification, search for etiology and therapeutic approach. Rev Med Interne 24(12):794–802. (French)
Braun J, Deodhar A, Inman RD et al (2012) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71(5):661–667
Cordero-Coma M, Calvo-Río V, Adán A, Blanco R, Álvarez-Castro C, Mesquida M, Calleja S, González-Gay MA, Ruíz de Morales JG (2014) Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediat Inflamm 2014:717598
Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V (2014) Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 22(2):90–95
This study was not supported by any of the company. None of the authors has financial or proprietary interests in any material or method mentioned. This data has not been previously published.
Involved in design and conduct of the study (UC, SY, MI); preparation and review of the study (NKY, AEB, SY); data collection (HS, EG, ID, MI, SY).
Conflict of interest
All authors report no financial conflicts of interest in this article
About this article
Cite this article
Yazgan, S., Celik, U., Işık, M. et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol 37, 139–145 (2017). https://doi.org/10.1007/s10792-016-0239-y
- Anterior Uveitis
- HLA-B27-positive ankylosing spondylitis